CPV containing vesicles I
BACKGROUND & SIGNIFICANCE
•Discovered May 1978 worldwide
•Suspected to have emerged from
feline panleukopenia virus
•Targets puppies less than 4
months or dogs that have not been
•High risk breeds are Rottweilers & BIOLOGY OF THE VIRUS/ VIRALI FUTURE DIRECTIONS
Doberman Pinchers LIFE CYCLE •Update current vaccine with new strain
•Symptoms include; lethargy, in • ssDNA virus of virus
appetence, fever, vomiting, & • linear genome of 5.2 kb& 25-27 nm •Improve diagnostic tests
diarrhea (often liquid and bloody) diameter •Continue to research the current
•Can damage the heart muscle in • icosahedron capsid composed of strains that are infecting canines
puppies < 10 wks and fetal puppies 60 copies
•Death can occur within 48-72 hrs worldwide
• 11 nucleotide oligomeric fragment
from onset of symptoms • Continue to educate puppy owners
• genome bound to 60 binding sites
•Cause of death is dehydration on inside surface of capsid
•High morbidity, high mortality • 2 ORF encode 4 proteins via References
(unless treated early) alternative splicing of the mRNAs
American Veterinary Medical Association (AVMA). 2006
•Infected > 80 % of domesticated & • non-enveloped •
Berns, Kenneth I. 1990. Parvovirus Replication. Microbiological
wild canids worldwide btwn 1978- • enters host cell via endocytosis •
Reviews 54(3): 316-329.
Chapman, Michael S. and Rossmann, Michael G. 1995. Single-
1979 • viral infectious entry pathway in stranded DNA-protein interactions in canine parvovirus. Structure
•Endemic pathogen & still a A72 cells begins w/ binding of itself • Langeveld, Jan P.M.; Casal, Ignacio J.; Osterhaus, Albert D.M.E.;
Cortés, Elena; Swart, Rik de; Vela, Carmen; Dalsgaard, Kristan; Puijk,
common cause of death in puppies to 40- to 42- kDa glycoproteins Wouter C.; Schaaper, Wim M.M.; and Meloen, Rob H. 1994. First
peptide vaccine providing protection against viral infection in the
•Medical treatment includes; fluids, • req. low pH to enter cytoplasm target animal: Studies of canine parvovirus in dogs. J Virol 68(7):
antibiotics (for secondary • endocytotic vesicles transport the • Martella, Vito; Cavalli, Alessandra; Decano, Nicola; Elia, Gabriella;
Desario, Costantina; Campolo, Marco; Bozzo, Giancarlo; Tarsitano,
infection), anti-emetics, heat virus into the nucleus for replication Elvira; and Buonavoglia, Canio. 2005. Immunogenicity of an
intranasally administered modified live canine parvovirus type 2b
support, plasma (severe cases) • host cells must be in S-phase b/c vaccine in pups with maternally derived antibodies. Clin Diagn Lab
•No re-infection ever documented virus req. DNA poly & more •
Immunol 12(10): 1243-1245.
Noel, Paige L. 2006. Veterinary Technician at California Veterinary
•Virus lives in the environment up replication machinery •
Specialists, San Marcos, California since 2003.
Parrish, Colin R. and Kawaoka, Yoshihiro. 2005. The origins of new
pandemic viruses: The acquisition of new host ranges by canine
to 7 years • replicates autonomously in rapidly parvovirus and influenza A viruses. Annu Rev Microbiol 59: 553-586.
•Contracted via ingestion of proliferating cells
• Suikkanen, Sanna; Sääjärvi, Katja; Hirsimäki, Jonna; Välilehto, Outi;
Reunanen, Hilkka; Vihinen-Ranta, Maija; and Vuento, Matti. 2002.
infected feces • rate of variation since 1978 has
Role of recycling endosomes and lysosomes in dynein-dependent
entry of canine parvovirus. J Virol 76(9): 4401-4411.
•Vaccine is available been ~ 1.7 x 10^-4/ site/ yr
• Vihinen-Ranta, Maija; Kalela, Anne; Mäkinen, Päivi; Kakkola, Laura;
Marjomäki, Varpu; and Vuento, Matti. 1998. Intracellular route of
canine parvovirus entry. J Virol 72(1): 802-806.